NO20076575L - Fremgangsmåte for fremstilling av triazol substituerte azaindoloksoeddikpiperazinderivater og nye saltformer derved fremstilt - Google Patents

Fremgangsmåte for fremstilling av triazol substituerte azaindoloksoeddikpiperazinderivater og nye saltformer derved fremstilt

Info

Publication number
NO20076575L
NO20076575L NO20076575A NO20076575A NO20076575L NO 20076575 L NO20076575 L NO 20076575L NO 20076575 A NO20076575 A NO 20076575A NO 20076575 A NO20076575 A NO 20076575A NO 20076575 L NO20076575 L NO 20076575L
Authority
NO
Norway
Prior art keywords
azaindolo
preparation
derivatives
prepared
oxoaceticpiperazine
Prior art date
Application number
NO20076575A
Other languages
English (en)
Other versions
NO341136B1 (no
Inventor
Roberto Droghini
Michael G Fakes
Shawn K Pack
Jean Lajeunesse
Pierre Sirard
Qi Gao
Nachimuthu Soundararajan
Yuping Qiu
Wenhao Hu
David R Kronenthal
Ramakrishnan Chidambaram
Xinhua Qian
Kenneth J Nathalie
Nathan Reising
Erqing Tang
Feng Qian
Blisse J Vakkalagadda
Chiajen Lai
Shan-Ming Kuang
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO20076575L publication Critical patent/NO20076575L/no
Publication of NO341136B1 publication Critical patent/NO341136B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/48—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups having nitrogen atoms of sulfonamide groups further bound to another hetero atom
    • C07C311/49—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups having nitrogen atoms of sulfonamide groups further bound to another hetero atom to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/26—Radicals substituted by halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

En fremgangsmåte er gitt for fremstilling av triazol substituert azaindoloksoeddiksyre piperazin-derivat. Nye mellomprodukter fremstilt i fremgangsmåten ovenfor og nye N-1 og amorfe former av en 1,2,3-triazol substituert azaindoloksoeddiksyre piperazin-derivater og fremgangsmåter for å produsere slike nye former er også gitt.
NO20076575A 2005-06-22 2007-12-20 Fremgangsmåte for fremstilling av triazol substituerte azaindoloksoeddikpiperazinderivater NO341136B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69300405P 2005-06-22 2005-06-22
PCT/US2006/024335 WO2007002308A2 (en) 2005-06-22 2006-06-21 Process for preparing triazole substituted azaindoleoxoacetic piperazine derivatives and novel salt forms produced therein

Publications (2)

Publication Number Publication Date
NO20076575L true NO20076575L (no) 2008-03-18
NO341136B1 NO341136B1 (no) 2017-08-28

Family

ID=37460063

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20076575A NO341136B1 (no) 2005-06-22 2007-12-20 Fremgangsmåte for fremstilling av triazol substituerte azaindoloksoeddikpiperazinderivater

Country Status (11)

Country Link
US (2) US7601715B2 (no)
EP (1) EP1907389B1 (no)
JP (1) JP5010593B2 (no)
CN (1) CN101243085A (no)
AR (1) AR055801A1 (no)
AT (1) ATE517898T1 (no)
ES (1) ES2368788T3 (no)
NO (1) NO341136B1 (no)
PE (1) PE20070122A1 (no)
TW (1) TW200740807A (no)
WO (1) WO2007002308A2 (no)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7601715B2 (en) * 2005-06-22 2009-10-13 Bristol-Myers Squibb Company Process for preparing triazole substituted azaindoleoxoacetic piperazine derivatives and novel salt forms produced therein
US7598380B2 (en) * 2005-08-03 2009-10-06 Bristol-Myers Squibb Company Method of preparation of azaindole derivatives
CA2730253A1 (en) * 2008-07-08 2010-01-14 Alphonso Higuera Novel crystalline form of 2-[4-(4-fluoro-benzyl)-piperidine-1-yl]-2-oxo-n-(2-oxo-2,3-dihydro-benzoxazol-6-yl)-acetamide
PT2323633E (pt) * 2008-09-04 2012-05-29 Bristol Myers Squibb Co Composição farmacêutica estável para a administração optimizada de um inibidor de união de hiv
RU2012146246A (ru) 2010-03-31 2014-05-10 Актелион Фармасьютиклз Лтд Антибактериальные производные изохинолин-3-илмочевины
WO2011130500A1 (en) * 2010-04-16 2011-10-20 Novartis Ag Formulations of a pyridazine bipyrazinyl
US20110263701A1 (en) * 2010-04-21 2011-10-27 Sigal Blau Gabapentin enacarbil compositions
CN102372707B (zh) * 2010-08-16 2015-08-19 上海药明康德新药开发有限公司 6-甲基-4-溴-1,6-二氢吡咯[2,3-c]吡啶-7-酮的合成方法
DK2670751T3 (en) * 2011-01-31 2015-07-20 Bristol Myers Squibb Co PROCEDURES FOR MANUFACTURING HIV BINDING INHIBITOR PRODUCT CONNECTION AND INTERMEDIATES
CN102993109A (zh) * 2012-12-03 2013-03-27 浙江工业大学 一种脒化合物的制备方法
JP6454707B2 (ja) * 2013-12-05 2019-01-16 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ｔｒａｎｓ−８−クロロ−５−メチル−１−［４−（ピリジン−２−イルオキシ）−シクロヘキシル］−５，６−ジヒドロ−４Ｈ−２，３，５，１０ｂ−テトラアザ−ベンゾ［ｅ］アズレン及びその結晶形態の合成
AR099677A1 (es) 2014-03-07 2016-08-10 Sumitomo Chemical Co Compuesto heterocíclico fusionado y su uso para el control de plagas
CN108863917A (zh) * 2017-05-16 2018-11-23 穆云 一种2,5-二甲氧基吡啶的制备方法
JP7429236B2 (ja) 2019-01-17 2024-02-07 ヴィーブ ヘルスケア ユーケー（ナンバー４）リミテッド ホステムサビルの調製方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3545461B2 (ja) * 1993-09-10 2004-07-21 エーザイ株式会社 二環式ヘテロ環含有スルホンアミド誘導体
ZA949293B (en) 1993-12-08 1995-08-17 Nihon Nohyaku Co Ltd Hydrazine derivatives and uses thereof
US6476034B2 (en) * 2000-02-22 2002-11-05 Bristol-Myers Squibb Company Antiviral azaindole derivatives
US20020061892A1 (en) 2000-02-22 2002-05-23 Tao Wang Antiviral azaindole derivatives
US20040110785A1 (en) * 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
EP1363705B9 (en) 2001-02-02 2012-11-07 Bristol-Myers Squibb Company Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US20030207910A1 (en) 2001-02-02 2003-11-06 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US20040063744A1 (en) 2002-05-28 2004-04-01 Tao Wang Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides
US7745625B2 (en) * 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
US20060100432A1 (en) * 2004-11-09 2006-05-11 Matiskella John D Crystalline materials of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
US7601715B2 (en) * 2005-06-22 2009-10-13 Bristol-Myers Squibb Company Process for preparing triazole substituted azaindoleoxoacetic piperazine derivatives and novel salt forms produced therein

Also Published As

Publication number Publication date
EP1907389B1 (en) 2011-07-27
PE20070122A1 (es) 2007-03-11
AR055801A1 (es) 2007-09-05
WO2007002308A9 (en) 2007-03-01
JP2008546795A (ja) 2008-12-25
EP1907389A2 (en) 2008-04-09
ATE517898T1 (de) 2011-08-15
WO2007002308A3 (en) 2007-07-12
US20100076191A1 (en) 2010-03-25
NO341136B1 (no) 2017-08-28
CN101243085A (zh) 2008-08-13
US20060293304A1 (en) 2006-12-28
ES2368788T3 (es) 2011-11-22
TW200740807A (en) 2007-11-01
JP5010593B2 (ja) 2012-08-29
WO2007002308A2 (en) 2007-01-04
US7968718B2 (en) 2011-06-28
US7601715B2 (en) 2009-10-13

Similar Documents

Publication Publication Date Title
NO20076575L (no) Fremgangsmåte for fremstilling av triazol substituerte azaindoloksoeddikpiperazinderivater og nye saltformer derved fremstilt
MY142768A (en) Gfat inhibitors
WO2004046148A8 (de) Neue xanthinderivate, deren herstellung und deren verwendung als arzneimittel
BG105177A (en) Novel substituted pyrazole derivatives
NZ592897A (en) Crystals of laquinimod sodium, and process for the manufacture thereof
NO20024644D0 (no) 4-amino-5-cyano-2-anilino-pyrimidinderivater og anvendelse derav som inhibitorer av celle cyclus kinaser
NO20071617L (no) Indozolonderivater som 11B-HSD1-inhibitorer
Singh Structural optimization of indole based compounds for highly promising anti-cancer activities: Structure activity relationship studies and identification of lead molecules
WO2005051300A3 (en) Bicyclic inhibitors of mek and methods of use thereof
CA2379026A1 (en) Substituted thiene-3-yl-sulphonylamino(thio)carbonyl-triazolin(thi)ones
NO330968B1 (no) Ny fremgangsmate for syntesen av (1S)-4,5-dimetoksy-1-(metylaminometyl)-benzocyklobutan og addisjonssalter derav, og anvendelse i syntesen av ivabradin og addisjonssalter derav med en farmasoytisk akseptabel syre
MX2007006549A (es) Procedimiento para preparar derivados condensados de piperazin-2-ona, asi como productos intermedios del procedimiento.
NO991761L (no) Nye piperidin-kotokarbonsyre-derivater, deres fremstilling og anvendelse
YU50002A (sh) Supstituisani piperidini, lekovi koji sadrže ova jedinjenja i postupci za njihovu proizvodnju
AU2003301508A1 (en) Processes for producing glutamic acid derivative and pyroglutamic acid derivative and novel intermediate for production
EP1516926A4 (en) PROCESS FOR THE PRODUCTION OF NERVOUS CELLS
MXPA05010875A (es) Derivados de piperazina como inhibidores de renina.
NO20070089L (no) DPP-IV inhibitorer
WO2007032028A8 (en) Thiazolinones and oxazolinones and their use as ptp1b inhibitors
TNSN07006A1 (en) Novel heterocyclic compounds
MXPA06013387A (es) Nuevos derivados de piridazinona como inhibidores de cdk2.
NO20062599L (no) Fremgangsmate for syntese av perindopril og farmasoytisk akseptable salter derav
ATE445617T1 (de) Chinolinderivat, dessen verwendung, herstellung und dieses enthaltendes arzneimittel
IL180312A0 (en) Process for preparing carboxamide pyridine derivatives used as intermediates in the synthesis of nk-1 recepor antagonists
MXPA05013537A (es) Derivados de indol.

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: VIIV HEALTHCARE UK (NO. 5) LIMITED, GB

MM1K Lapsed by not paying the annual fees